Compare Chart Industries Inc (GTLS) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chart Industries Inc vs Zimmer Biomet Holdings Inc — how do they compare? Chart Industries Inc trades at $209.97 (market cap $10.05B), while Zimmer Biomet Holdings Inc trades at $93.05 (market cap $17.44B). The key difference: Zimmer Biomet Holdings Inc is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 1.07% dividend while Chart Industries Inc pays none. Which is the better fit depends on your goals.
| GTLS | ZBH | |
|---|---|---|
Market Cap | $10.05B | $17.44B |
Sector | Technology | Health |
52-Week High | $209.91 | $107.71 |
52-Week Low | $167.29 | $79.58 |
Enterprise Value | $13.57B | $24.49B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GTLS trades at $209.97, up 0.03% on the day, with a bullish technical outlook supported by moving averages but overbought RSI signals. The company reported $4.26B in 2025 revenue but missed earnings estimates for three consecutive quarters, with a negative net income margin of -0.62%. Recent news highlights Baker Hughes' pending $13.6B acquisition, which received conditional EU approval in July 2026, potentially driving investor optimism.
The stock's outlook is mixed: strong analyst buy consensus (54%) and acquisition prospects offer upside, but weak profitability and earnings misses pose risks. Investors should weigh the acquisition's completion against fundamental challenges like negative ROE and high P/E of 629.67, indicating premium valuation despite profitability concerns.
Zimmer Biomet (ZBH) trades at $92.94, up 2.1% on the day, with a bullish technical signal and consistent earnings beats. The stock shows strong fundamentals with a 70% gross margin and positive cash flow trends, though net income margin has declined from 13.8% in 2023 to 8.6% in 2025. Recent developments include expansion in Asia Pacific and a planned $1 billion share repurchase, indicating management confidence.
ZBH presents a moderate growth opportunity with a consensus price target of $97.67, offering ~5% upside. Risks include rising debt levels and competitive pressures in medical devices. Analyst sentiment is mixed with 40% buy ratings, but institutional activity and strategic acquisitions support a stable outlook for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chart Industries Inc
Chart Industries is a leading manufacturer of highly engineered cryogenic equipment. Its products are used throughout the liquid gas supply chain, including clean energy applications like hydrogen and LNG.
Read more on GTLS →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
